<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01771549</url>
  </required_header>
  <id_info>
    <org_study_id>12-007541</org_study_id>
    <nct_id>NCT01771549</nct_id>
  </id_info>
  <brief_title>Kinetics of Troponin and BNP in Breast Cancer Chemotherapy With Adriamycin and Trastuzumab</brief_title>
  <official_title>Pilot Study of the Kinetics of High Sensitivity Troponin and Brain Natriuretic Peptide in Breast Cancer Chemotherapy With Adriamycin and Trastuzumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study involves very frequent monitoring of breast cancer patient blood levels of&#xD;
      hs-cTnT Troponin and n-t-BNP (Brain Natriuretic Peptide) before and after initiation of&#xD;
      chemotherapy with either adriamycin or trastuzumab in order to define the kinetics of both&#xD;
      biomarkers during the first two cycles of chemotherapy. Cardiac troponins and BNP are&#xD;
      frequently elevated after experimental chemotherapy in animal models. Their behavior in&#xD;
      humans has been inconsistent, with occasional elevations seen, usually within 30 days of&#xD;
      therapy. Assays for troponin with sensitivity into the pg/ml range have now been introduced.&#xD;
      A majority of patients greater than age 50 have elevations above the detection limit,&#xD;
      compared to only 1-3% with conventional troponin assays, and over 90% of diabetics have&#xD;
      elevations above the detection limit. Moreover, augmented release of high sensitivity&#xD;
      troponin is detected after exercise or rapid atrial pacing of durations of 10-15 minutes in&#xD;
      patients with and without coronary artery disease. This improved sensitivity suggests the&#xD;
      potential for detection and monitoring of cardiac damage after cancer chemotherapy. We&#xD;
      hypothesized that this new generation of troponin assay would be associated with kinetic&#xD;
      behavior suggesting ongoing cardiac damage with anthracycline therapy, and possibly also with&#xD;
      trastuzumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Collect blood samples in two groups of patients (n=10 per group) for amino-terminal brain&#xD;
      natriuretic peptide (n-t-BNP) and high sensitivity cardiac troponin T (hs-cTnT):&#xD;
&#xD;
        -  Group 1 (adriamycin) will consist of patients beginning clinically indicated&#xD;
           chemotherapy for breast cancer with a dose-dense (every 2 week) regimen. including&#xD;
           adriamycin (n=10).&#xD;
&#xD;
        -  Group 2 will include patients who receive trastuzumab in the adjuvant or (neo) adjuvant&#xD;
           setting, or in a metastatic setting in a regimen that does not include simultaneous&#xD;
           adriamycin.&#xD;
&#xD;
      Blood samples for hs-cTNT and n-t-BNP will be obtained on days pre-treatment, and&#xD;
      post-treatment days 1, 2, 3, 7, pre-cycle 2, and post-cycle 2 days 1,2,3 and 7. The interval&#xD;
      for treatment is usually two weeks for adriamycin and three weeks for trastuzumab. We will&#xD;
      identify frequency of detectible levels above the detection limit and above the baseline,&#xD;
      peak values and area under the curve. Enrollment of up to 15 per group will be allowed to&#xD;
      guarantee acquisition of 10 full sets of samples. Lab draw from chemotherapy ports will be&#xD;
      allowed. We plan to store specimens for future analyses with more sensitive assays in&#xD;
      development.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 26, 2017</completion_date>
  <primary_completion_date type="Actual">June 26, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>one year</time_frame>
    <description>Concentration-time plots from pre-treatment through days 1,2,3,7,and pre-cycle two</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline to peak</measure>
    <time_frame>1 year</time_frame>
    <description>The difference between the pretreatment value and the highest level on days 1,2,3 or 7</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Descriptive statistics</measure>
    <time_frame>1 year</time_frame>
    <description>Descriptive statistics will be used to describe the quantitative values, and frequencies above and below the detection limit, time to peak, and amplitude of peak versus baseline values for both n-t-BNP and hs-cTnT.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">26</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Patients with breast cancer beginning chemotherapy with a dose-dense regimen including adriamycin without concurrent trastuzumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Patients receiving trastuzumab in the adjuvant, neo-adjuvant, or metastatic setting in a regimen not containing simultaneous adriamycin therapy.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood 10 ml per draw, yielding 5 ml of serum. After testing, the remaining serum will&#xD;
      be stored.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Mayo Clinic Florida female, adult patients from Hematology/Oncology Department undergoing&#xD;
        clinically-indicated treatment for breast cancer which includes either, but not both,&#xD;
        adriamycin or trastuzamab will be eligible to participate&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female adult patients aged 18+&#xD;
&#xD;
          -  Group 1: beginning clinically- indicated chemotherapy for breast cancer with a&#xD;
             dose-dense (every 2 weeks) regimen including adriamycin (n=10).&#xD;
&#xD;
          -  Group 2: patients who receive trastuzumab in and adjuvant, (neo) adjuvant, or&#xD;
             metastatic setting in a regimen that does not include simultaneous adriamycin.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to return to the clinic for regular phlebotomy&#xD;
&#xD;
          -  Baseline hemoglobin &lt; 10 gm/dl&#xD;
&#xD;
          -  Creatinine clearance &lt; 60 ml/minute (this effects troponin clearance)&#xD;
&#xD;
          -  Recent (&lt; 3 months) cardiac surgery, myocardial infarction, unstable angina, or&#xD;
             hospitalization for congestive heart failure&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph L Blackshear, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Advani P, Hoyne J, Moreno-Aspita A, Dubin M, Brock S, Harlow C, Chumsri S, Suter T, Blackshear JL. High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy. Chemotherapy. 2017;62(6):334-338. doi: 10.1159/000477797. Epub 2017 Jul 14.</citation>
    <PMID>28704807</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>January 14, 2013</study_first_submitted>
  <study_first_submitted_qc>January 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2013</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Joseph L. Blackshear</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Adriamycin</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Brain Natriuretic Peptide (BNP)</keyword>
  <keyword>Troponin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

